MetaCap

Avalo Therapeutics Statistics

NASDAQ: AVTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD

6.76+0.01 (+0.15%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

Avalo Therapeutics by the numbers

Avalo Therapeutics has a market capitalization of $390.9 million based on 57.82M shares outstanding. With trailing EPS of $-2.26, Avalo Therapeutics is unprofitable on a 12-month basis, so earnings-based valuation ratios do not apply. The stock trades 39.7% below its 50-day average and 56.2% below its 200-day average.

Average daily trading volume is 1.80M shares, or about $12.2 million in dollar volume.

Summary generated from market data by MetaCap's automated system. Methodology

AVTX valuation vs. peer median

AVTX compared with the median of 8 peer companies
MetricAVTXPeer medianDifference
Market cap$390.88M$389.50M+0%
Avg. volume1.80M963.48K+87%

Peer median across 8 companies: OCS, IRD, PHAT, OVID, PBYI, CRMD, ASPE, PRTA.

Valuation

Market cap
$390.88M
Price / sales (latest FY)
6,625.15
EPS (TTM)
$-2.26

Price and trading

Previous close
6.75
Open
6.65
Day range
6.61 – 7.03
52-week range
6.53 – 24.27
52-week change
-62.09%
Beta
—
Volume
1.18M

Dividends and events

Annual dividend
None

Additional statistics

Market Cap
390.88M
Forward Pe
-2.58
Eps
-2.26
Dividend Yield
0.00%
Dividend Rate
0.00
Week52 High
24.27
Week52 Low
6.53
Avg Volume
1.80M
Shares Outstanding
57.82M
Ma50
11.21
Ma200
15.43
Earnings Date
Nov 5, 2026
Pct From52w High
-72.15%
Pct From52w Low
3.52%

Related